Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021-2022.

Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021-2022.

Publication date: Jan 07, 2024

In 2021-2022, most of the Spanish population received COVID-19 vaccines and a high proportion of them had SARS-CoV-2 infection. We estimated the rate of hospitalisations and deaths that were averted by risk reduction among vaccinated COVID-19 cases. Hospitalisations and deaths were analysed among COVID-19 cases confirmed in 2021 and 2022 in Navarre, Spain. To calculate the number of prevented outcomes by sex, age, comorbidities, and semester, the difference in the risk of each outcome between unvaccinated and vaccinated cases was multiplied by the number of vaccinated cases. COVID-19 vaccination coverage with any dose reached 88%, 86% with full vaccination, and 56% with a booster dose. The cumulative rates per 1000 inhabitants were 382 COVID-19 confirmed cases, 6. 70 hospitalisations, and 1. 15 deaths from COVID-19. The estimated rates of prevented events by vaccination were 16. 33 hospitalisations and 3. 39 deaths per 1000 inhabitants, which was 70. 9% and 74. 7% of expected events without vaccination, respectively. People aged 80 years and older or with major chronic conditions accounted for the majority of hospitalizations and deaths prevented by COVID-19 vaccination. One hospitalisation and death due to COVID-19 were averted for every 53 and 258 people vaccinated, respectively. The high COVID-19 vaccine effect in reducing the risk of severe outcomes and the high vaccination coverage in risk populations prevented three out of four hospitalisations and deaths due to COVID-19 during a period of intense circulation of SARS-CoV-2.

Open Access PDF

Concepts Keywords
Basel COVID-19 hospitalisation
Death COVID-19 mortality
Hospitalizations COVID-19 vaccination
Spanish SARS-CoV-2
vaccination effectiveness
vaccination impact


Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO population
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccinated
disease VO unvaccinated
disease VO vaccination coverage
disease VO dose
disease MESH chronic conditions
disease MESH death
disease VO COVID-19 vaccine
disease VO vaccination dose
disease VO vaccine
disease VO effectiveness
disease MESH infections
disease VO Comirnaty
drug DRUGBANK Coenzyme M
disease VO time
disease VO vaccine effectiveness
disease VO vaccine dose
disease MESH cardiovascular diseases
disease MESH diabetes mellitus
disease MESH liver cirrhosis
disease MESH chronic kidney disease
disease MESH chronic obstructive pulmonary diseases
disease MESH asthma
pathway KEGG Asthma
disease MESH dementia
disease MESH stroke
disease MESH rheumatic diseases
disease MESH cancer
disease VO age
disease IDO infection
drug DRUGBANK Spinosad
disease VO efficiency
disease MESH reinfections
disease MESH comorbidity
disease VO protocol
drug DRUGBANK Allylestrenol
drug DRUGBANK (S)-Des-Me-Ampa
disease VO USA
disease VO Canada
disease VO organization

Original Article

(Visited 1 times, 1 visits today)